New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
Both organisations enter into a long- term collaboration to expand patient access in India
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs
Zydus Lifesciences receives EIR report from USFDA for API Ahmedabad facility
Nectar Lifesciences has clarified that the company has no relation/connection/ association or link of any nature with the Nectar Herbs and Drugs
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
Subscribe To Our Newsletter & Stay Updated
